Advertise on podcast: Beginner's Mind

The trait a Silicon Valley AI investor rewards most in a management team has a name almost nobody uses: XQ. IQ brings the idea and EQ reads the people across the table. The execution quotient shows in something as small as how fast a team follows up after a meeting, and in her experience the people who score high on it have no patience for those who do not. Meanwhile the money in AI moves in waves, from models to tools to packaged products, and only some of those waves leave room for an early-stage fund. Ivy Nguyen is a Partner at GFT Ventures in Palo Alto, the early-stage firm founded by former NVIDIA and Samsung executives to invest in AI and frontier technology. She has looked at more than ten thousand AI pitches. In part two she explains her place on a board when investors and customers are angry at the same time, why market pull is a strong but incomplete signal, how she tells a feature from a platform, how a no from her firm is framed, how AI booms move from models to picks and shovels, why AI takes over tasks long before it replaces a role, and why care coordination is worth more in healthcare than AI note-taking. Part one is EP 184: [EP 184 LINK] WHAT YOU WILL LEARN What a good investor does when a company’s investors and customers are angry at the same timeHow IQ, EQ and XQ, the execution quotient, show up in a management teamHow to tell a feature with a short life from a platform that lastsWhy AI booms move from models to picks and shovels to vertical applicationsWhy AI removes tasks long before it replaces whole rolesBEST QUOTES (00:04:30) “The CEO is very much the captain. I am merely a passenger, a very annoying backseat driver.”(00:09:25) “XQ is execution quotient. How quickly do they follow up after meetings?”(00:22:57) “I want to be wrong. Then come back and show me, and I will continue the conversation.”(00:33:29) “People who struck gold figuratively were the people who were selling picks and shovels.”(00:46:24) “You can’t automate, and you can’t replace, what you don’t understand.”TIMESTAMPS THE INVESTOR’S SEAT (00:00:00) Intro to part two(00:01:39) When investors and customers are both angry(00:02:31) Captain and backseat driver, the investor’s placeHOW SHE JUDGES A COMPANY (00:07:42) Market pull and the execution quotient(00:12:28) Christian Soschner tests market pull against NVIDIA and Amazon(00:16:33) Feature or platform, the follow-up question she always asks(00:20:52) Direct and kind, how a no from GFT is framedTHE AI MARKET TODAY (00:25:56) Inside GFT Ventures, a contrarian AI fund(00:30:37) How AI booms move from models to picks and shovels(00:36:06) Vertical AI and the data a competitor cannot buy(00:40:15) Why AI takes over tasks long before whole roles(00:49:54) Care coordination beats AI note-taking in healthcareWHAT COMES NEXT (00:55:44) Her ten-year prediction, the future arrives faster(00:59:45) How to get a busy investor to answer your email(01:01:00) Closing thoughtsIvy Nguyen at GFT Ventures: https://www.gft.vc/ivy-nguyen Ivy Nguyen on LinkedIn: https://www.linkedin.com/in/ivyknguyen/ Newsletter: https://lsg2g.substack.com/ Follow Beginner’s Mind for long-form conversations on leadership, capital, technology, and the people building what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

In 2017 another investor told Ivy Nguyen that artificial intelligence was too small a niche to dedicate a fund to. More than ten thousand AI pitches later, every pitch deck says AI. Single funding rounds have grown larger than entire venture funds, and from the outside the companies that will matter look exactly like the ones a fast follower overtakes within three years. Ivy Nguyen is a Partner at GFT Ventures in Palo Alto, the early-stage firm founded by former NVIDIA and Samsung executives to invest in AI and frontier technology. Before GFT she held investment roles at Zetta Venture Partners, Point72 Ventures and Autotech Ventures. She studied chemical engineering at Stanford and was named to Forbes 30 Under 30. In part one she explains why Silicon Valley money backs the vision before the plan, how a first company that ran out of cash led her into venture capital, why she passed on Coinbase twice, the test every AI company has to pass at her firm, and why the early AI businesses that passed it still ran on 30 to 40 percent margins. Part two continues in EP 185. WHAT YOU WILL LEARN Why Silicon Valley investors fund the size of the vision before the plan to reach itWhy a strong business from another market can lose a Silicon Valley pitch in the first thirty minutesHow passing on Coinbase twice led her to specialise in AIThe billion-dollar test, and why proprietary data is the one advantage money cannot buyWhy AI products that work in the lab lose accuracy and margin in the fieldBEST QUOTES (00:08:35) “The number one most common cause of death for every startup is cash flow.”(00:23:03) “In a two to three ton piece of metal on the highway, I don’t want it figured out along the way.”(00:33:56) “I actually passed on Coinbase two times, because I didn’t know what I was looking at.”(00:39:53) “Niche implies that it’s small. I’d like to use the word obscure.”(00:44:54) “Even $100 billion would not allow a copycat to brute force that level of performance.”TIMESTAMPS HOW AN AI INVESTOR IS MADE (00:00:00) Opening, the investor who called AI too small a niche(00:03:35) Chemical engineering, a first company and no plan B(00:08:35) The number one cause of death for every startupSILICON VALLEY AND EVERYWHERE ELSE (00:09:48) Why Stanford money backs the vision before the plan(00:15:54) Gold, defence research and the roots of Silicon Valley(00:22:35) Why a car at highway speed needs more proof than a grocery app(00:25:35) Seven years per car model, one weekend per software release(00:28:35) Growing up in Vietnam, where failure is sharedBUILDING CONVICTION IN AI (00:33:41) Why Ivy Nguyen passed on Coinbase twice(00:35:43) A crypto fund or an AI fund, the 2017 coin flip(00:38:33) Ten thousand AI pitches and the empress of obscureTHE INVESTMENT TEST (00:43:20) The billion dollar test and the proprietary data flywheel(00:46:32) Why ten years is the real deadline in venture capital(00:51:25) Why AI companies once ran on 30 percent marginsIvy Nguyen at GFT Ventures: https://www.gft.vc/ivy-nguyen Ivy Nguyen on LinkedIn: https://www.linkedin.com/in/ivyknguyen/ Newsletter: https://lsg2g.substack.com/ Follow Beginner’s Mind for long-form conversations on leadership, capital, technology, and the people building what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

A seed investor at Novo Holdings would rather read your rough idea than your finished pitch deck. Most founders spend a year building the deck, forming the team and waiting until the story holds together. By the time it is ready the science has moved, the money has gone somewhere else, and nobody told them the fund they were preparing for creates companies out of raw material. Marie Schroeder is a Principal on the Seed Investments team at Novo Holdings, the investment company owned by the Novo Nordisk Foundation. Before that she spent five years at Novo Nordisk in cardiovascular drug development. Before that, a doctorate at Oxford and research work in Toronto. Beginning with what a seed investor watches at the start of a year, the conversation becomes a practical guide to building and funding early biotech: the question her chief scientific officer put to every project until it hurt, what to do in the first hour after a negative readout, why the founder who discovered the science is often the wrong person to run the company, and how her team tracked one Swedish heart failure company for three years before a single risk cleared and the money moved. WHAT LISTENERS CAN EXPECT TO LEARN Why defining what good looks like before the experiment runs decides whether a failed program gets funded twiceHow to break a plan into killer experiments so each tranche of money buys one specific answerWhat a board wants to hear on the day something fails, and how early it wants to hear itWhy team quality beats science quality in early biotech, argued on commercial groundsWhat a seed fund actually wants in a cold approach, and why a rejection is usually about timingBEST QUOTES (00:14:09) "Defining what good looks like before you start the experiment is absolutely paramount."(00:22:42) "The target failing is one of maybe five things that could have gone wrong."(00:52:36) "He only has time to give the negative feedback. Every other paragraph was good."(01:15:58) "You can have great science, and if you don't have the right team, it will fail."(01:35:47) "I would rather somebody send a rough concept than spend half their life making a pitch deck."TIMESTAMPS THE YEAR AHEAD (00:00:00) Intro(00:02:35) What is on top of a seed investor's mind this year(00:05:43) The muscle loss problem inside the obesity storyRESILIENCE AND FAILURE (00:10:45) What resilience means to a biotech investor(00:14:09) What does good look like, the question behind every project(00:18:42) Killer experiments and what has to be true next(00:22:03) The first hour after a negative readout(00:27:19) Learning resilience without joining Special ForcesFEEDBACK, BOUNDARIES AND BAD NEWS (00:45:52) Compromise, burnout and anger out of proportion(00:51:18) The Oxford professor who wrote nonsense on the draft(00:57:25) Jensen Huang, no firings and torture them to greatnessFROM OXFORD TO NOVO HOLDINGS (01:02:15) Academics are the true scientists, the belief she dropped(01:07:51) Novo Nordisk, Novo Holdings and the foundation explained(01:12:26) Two lessons from five years inside Novo NordiskWHO BUILDS THE COMPANY (01:15:49) Why diverse teams are non-negotiable in biotech(01:21:31) Why the scientific founder should not be CEOGETTING FUNDED (01:33:54) The minimum a cold pitch deck needs(01:39:55) The company they watched for three years(01:50:46) Venture capital as a self-fulfilling prophecyWHAT COMES NEXT (01:55:13) Two directions pharma has to run at once(02:01:28) Closing thoughtsMarie Schroeder at Novo Holdings: https://novoholdings.dk/people/marie-schroeder Newsletter: https://lsg2g.substack.com/ Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

What does it mean when the most respected adviser in Silicon Valley tells you that you are the best chief executive he works with, while your company is heading straight into a wall? Bill Campbell said exactly that to Ben Horowitz. Campbell was advising Steve Jobs, Jeff Bezos and Eric Schmidt at the time, so Horowitz assumed the compliment was absurd. Campbell explained himself: there are plenty of good peacetime chief executives and plenty of good wartime ones, and almost nobody who can do both. Horowitz's own accounting of his career: peacetime chief executive for three days, wartime chief executive for eight years. This is the second half of a review of The Hard Thing About Hard Things. Part one covered how to survive the worst weeks. This half is about the job itself, and the way it changes underneath you while you are busy doing it. [AFFILIATE LINK TO THE BOOK] Four lessons, and two places where I part company with the book. Wartime CEO, peacetime CEO. Two situations that reward opposite behaviour, and the sixteen contrasts Horowitz draws between them. My first disagreement: his wartime leader is loud, and the ones I have watched save companies are calm, well dressed and listening. Volume is not decisiveness, and a generation of founders read that list and concluded otherwise. My second: Horowitz treats wartime as an episode. In deep tech and life science it is the standing condition, for decades. Moderna, BioNTech and Katalin Karikó are the evidence, and the numbers are in the episode. Ones and Twos. The chief executive's job splits into knowing what to do and getting the company to do it, and founders reliably come apart on the second one. Where I push back: at scale, the first skill is not knowing the answers. It is judging who has them, and holding one story that points a hundred expert answers in the same direction. Horowitz's own book says so in two passages he files under a different heading. Why the impressive senior hire produces nothing. Three new initiatives a quarter in a large company. Eight to ten a day in a small one. Rhythm mismatch, skill mismatch, the three interview questions that expose both, and what Berkshire Hathaway did when it faced the biggest succession in modern corporate history. Look for a market of one. Thirty investors say no and one says yes, and the round is closed. Why most of those thirty were never a judgment about your company, how to tell a fit rejection from a real one, and the discipline that keeps this from becoming permission to stop listening. This is a practical review for founders, chief executives, board members, investors and senior executives who build or finance hard companies, particularly in deep tech and life sciences. Part one is the previous episode, and it stands on its own if you want to start there. Chapters (00:00) Introduction: Two Chief Executives, Two Different Jobs  (01:30) Lesson 4: Wartime CEO, Peacetime CEO, and Why Running the Wrong One Kills Companies  (16:38) Lesson 5: Ones and Twos, and the Half of the Job Founders Get Wrong (28:26) Lesson 6: Why the Impressive Hire From the Big Company Produces Nothing  (40:26) Lesson 7: Look for a Market of One, and What a Rejection Really Means  (50:16) Key Takeaways and Wrap Up Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

What do you do on the morning when there are no good moves left? In March 2001, Ben Horowitz took Loudcloud public in the middle of the dot-com collapse. The bankers cut the price from ten dollars a share to six in the week of the offering. The day before the deal, Yahoo announced its chief executive was stepping down. Neither of the two banks that took the company public offered the traditional closing dinner. On the plane home, Horowitz turned to his director of finance and said they had done it. The reply was that the company was still in very serious trouble. He was right. What followed was a share price of thirty-five cents, three rounds of layoffs, four hundred people gone, and business magazines running cover stories on the collapse. Six years later the same company sold to Hewlett-Packard for 1.6 billion dollars. The distance between those two moments is The Hard Thing About Hard Things, and it is the rare book about building companies written from inside repeated near-death rather than reconstructed afterwards from the winner's chair. [AFFILIATE LINK TO THE BOOK] Horowitz opens by attacking the genre he is writing in. Most management books offer a recipe. He argues that the situations which decide a company have no recipe, and that hunting for one is itself the failure. He then organises the book around that claim, putting the endgame material first, and explains the choice by quoting the first principle of the Bushido: keep death in mind at all times. Part one of this review covers the three lessons that belong together. The Struggle. Horowitz names the psychological state every founder recognises and almost nobody describes out loud, and then refuses to sell a way out of it. What he offers instead is a set of survival habits and one instruction: find the move. CEOs should tell it like it is. Shielding a team from bad news feels like leadership and works like sabotage. Trust is communication bandwidth. A brain cannot solve a problem it does not know about. And a healthy culture is one where bad news travels faster than good news. Lay people off yourself. The hardest act in the book, executed as a written procedure rather than improvised on the day. Why the manager has to do it rather than HR, why a layoff and a performance firing are two different acts that companies constantly blur, and why the message is always for the people who stay. Along the way: what Jensen Huang at Nvidia and Roland Busch at Siemens have in common, why Dale Carnegie's most famous principle has aged into something he never intended, and where Reed Hastings and Ben Horowitz disagree about what you owe the person you are letting go. This is a practical review for founders, CEOs, board members, investors and senior executives who build or finance hard companies, particularly in deep tech and life sciences, where the conditions Horowitz calls wartime are the default rather than the exception. Part two covers the remaining four lessons: wartime and peacetime leadership, the two halves of the chief executive's job and the half where founders reliably come apart, why the impressive executive you hire out of a large company so often produces nothing, and the rule about raising money that changes what a rejection means. Chapters (00:00) Introduction: The Least Celebratory IPO in History  (02:26) The Big Idea: Keep Death in Mind at All Times  (04:16) Who Is Ben Horowitz, and Why Trust Him  (08:55) Lesson 1: The Struggle, and Why No Formula Exists  (20:37) Lesson 2: CEOs Should Tell It Like It Is, and Why Trust Is Bandwidth  (32:26) Lesson 3: Lay People Off Yourself, Because the Message Is for the People Who Stay  (45:21) What Comes in Part Two Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

What happens when the moment a company finally succeeds is the moment it becomes most likely to be destroyed? Most founders assume the market rewards the better product and protects what they built. The legal reality runs the other way. The dominant theory of the corporation treats a company as a financial instrument designed to enrich its shareholders, and treats everything else as optional. That theory has a name, shareholder primacy, and nobody voted for it. It hardened in courtrooms and boardrooms about forty years ago. Founders sign it into their own charter on day one without reading the line, and by the time the gap between the mission statement and the legal purpose becomes visible, the exit has been engineered. Eric Ries, founder of the Long-Term Stock Exchange and author of The Lean Startup, explains how corporate purpose disappeared out of the legal documents and what can be put back in its place. He shows why protection alone makes an extractive company worse, why independent directors are not neutral, and why a mission guardian belongs above the board rather than inside it. Beginning with the pattern he watched destroy company after company, the conversation becomes a practical guide to governance: the three-legged stool of 19th century corporate law, what actually killed Sears, why Novo Nordisk, Patagonia, IKEA and Grundfos outlive their competitors, and how the Public Benefit Corporation restores something far older than it looks. It ends on the question neither of us could fully answer. If a guardian protects the mission, who guards the guardian? WHAT LISTENERS CAN EXPECT TO LEARN Why shareholder primacy is a recent legal theory rather than a permanent feature of capitalismHow the phrase "any lawful act or activity" removed purpose from corporate charters, and what quietly replaced itWhy structure protects an ethos but cannot create one, and what has to be real before the protection is addedHow industrial foundations, purpose trusts and public benefit corporations keep a mission alive across generationsWhy independent directors have incentives of their own, and what to look for in a board insteadBEST QUOTES (00:04:10) "A company is just a financial instrument, designed to enrich itself and its shareholders." — Eric Ries(00:14:12) "If you go to your local park, you'll find trees older than shareholder primacy." — Eric Ries(00:25:28) "Somebody took over Sears and managed to extract for himself $1.5 billion, at a time when the company lost $11 billion." — Eric Ries(00:40:09) "Who would you rather die than betray?" — Eric Ries(00:48:12) "Being a leader is much more like being a mother than a slave owner. We birth these things. We do not own them." — Eric RiesTIMESTAMPS  (00:00:00) Why Good Companies Go Bad After Success  (00:02:43) What Made Eric Ries Write Incorruptible  (00:04:10) A Company Is Just a Financial Instrument  (00:07:03) The Pill You Swallow and the Shareholder Calculation  (00:15:48) The Three-Legged Stool of Corporate Law  (00:19:31) How "Any Lawful Act or Activity" Erased Purpose  (00:25:28) What Actually Happened to Sears  (00:30:38) Stainless Steel for Organizations That Last  (00:34:39) Why Foundation-Owned Companies Outlive the Rest  (00:37:59) The Public Benefit Corporation Explained  (00:44:40) Why Every Company Needs a Mission Guardian (00:50:22) Why Independent Directors Are Not Neutral  (00:53:11) Who Guards the Mission Guardian  (00:56:18) What AI Changes for Governance  (00:59:58) Closing Thoughts Eric's book, Incorruptible: https://amzn.to/3S4n4BN If you'd like to keep talking about these topics, you're welcome to join Eric's free Incorruptible community here: https://community.incorruptible.co/ Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next. Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

What happens when the instinct to help a struggling company is exactly what prevents the strongest companies from succeeding? Venture capital forces investors to make decisions that can feel deeply uncomfortable: stop rescuing the weakest, concentrate scarce capital behind the most promising, and accept that most investments will fail. Deep tech intensifies this conflict. Investors must commit capital while the technology remains unproven, customers are still uncertain and the eventual exit may be more than a decade away. The wrong team, an inflated valuation or a fund timeline that does not fit the technology can destroy an otherwise promising company. Joško Bobanović, Partner at Sofinnova, explains how experienced investors make these decisions without ever receiving complete information. He reveals why people matter more than patents, why founders must start selling before they have a product and why investors should support management from the back seat—without trying to drive the company themselves. Beginning with a destructive storm Joško predicted but could not prevent, the conversation develops into a practical guide to risk, patience and capital allocation. It also confronts Europe’s central deep-tech challenge: the continent produces exceptional science, but without sufficient scale-up capital, specialist investors and corporate buyers, much of the value will be created elsewhere. WHAT LISTENERS CAN EXPECT TO LEARN Why successful venture investing requires resisting the instinct to rescue struggling portfolio companiesHow investors make consequential decisions with partial information—and recognize when it is time to stop researchingWhy the team, storytelling and customer conversations can matter more than exceptional technology aloneHow inflated valuations, ten-year fund structures and limited exit opportunities affect deep-tech companiesWhat Europe must change to scale its best companies instead of watching them industrialize elsewhereBEST QUOTES (00:20:04) “The nature of venture capital decisions is very counter to human instincts.” — Joško Bobanović(00:41:05) “Investment in a startup is like a marriage that is predetermined with a divorce at some point in time in the future.” — Joško Bobanović(00:54:25) “Nothing validates what you’re doing better than cash.” — Joško Bobanović(00:57:35) “A B team will probably destroy exceptional technology, but an A team will make a success even of average technology.” — Joško Bobanović(01:56:22) “Otherwise we become a museum. And I don’t think we want to be a museum.” — Joško BobanovićTIMESTAMPS (00:00:00) Why Venture Capital Fights Human Instinct (00:03:08) The Storm Joško Predicted but Could Not Stop (00:09:11) How the Early Internet Changed Access to Opportunity (00:16:49) If You Do Not Play, You Cannot Win (00:20:04) Why Investors Must Resist the Rescue Instinct (00:29:33) Scientists Must Learn to Decide with Partial Information (00:35:58) Can Founders Make Themselves Replaceable? (00:41:05) A Marriage with a Predetermined Divorce (00:47:45) Why Storytelling Is a Critical Deep-Tech Skill (00:52:03) Start Selling from Day One (00:57:03) Why Venture Capital Is a People Business (01:00:11) Investors Belong in the Back Seat (01:10:50) Better Decisions Require Broader Comparisons (01:18:00) When a Higher Valuation Becomes Dangerous (01:27:15) Why Every Venture Investment Needs 10× Potential (01:37:29) Deep Tech’s Missing Exit Opportunities (01:45:05) Why VCs See IPOs as a Necessary Evil (01:52:49) Europe’s Scientific Strength and Scale-Up Weakness (02:05:01) What Europe Gets Wrong About Failure (02:13:13) Get Involved Instead of Complaining from the Sidelines Follow Beginner's Mind for long-form conversations on leadership, capital, technology, and the people shaping what comes next.  Ranked in the global top 10% of all podcasts, named #1 Deep Tech Podcast in 2025, and #8 Deep Tech Podcast in 2026 Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

How can a company have the right numbers and still reach the wrong strategic conclusion? In 2017, Volkswagen’s chief executive mocked Tesla as one of the “world champions of big announcements.” At the time, Volkswagen sold roughly eleven million cars a year, while Tesla sold fewer than eighty thousand. The facts supported the criticism, but the conclusion missed the change already underway. That moment explains why Elon Musk remains worth studying. Most public discussion focuses on his personality, political views, wealth, or communication style. This episode takes a different approach and examines the methods that allowed him to enter industries dominated by governments and large corporations, pursue ideas that initially appeared uneconomic, and force entire markets to reconsider what could be built. The starting point is Eric Jorgenson’s The Book of Elon, which brings together more than two decades of Musk’s interviews, speeches, podcasts, and public writing. Jorgenson has already done the first stage of the work by reducing a vast archive to the statements that best explain how Musk thinks about purpose, engineering, talent, production, and company building. Because the book is itself a quote summary, I treated it as raw material rather than as a conventional biography. I selected seven recurring principles and tested them against more than 25 years of my own company-building experience. That includes six years in public-market M&A and two decades building biopharma and medtech companies from Series A toward IPO across more than seven company journeys. I also draw on several Musk biographies, years of long-form podcast interviews, and his public writing on X. The result is not another biography, and it is not an argument that every founder should copy Elon Musk. It is a practical framework for founders, CEOs, board members, investors, scientists, and senior executives who build or finance hard companies. The central question is straightforward: What can you copy from Elon Musk without copying the personality? The episode examines why utility matters more than glory, why important companies often have to build before market permission arrives, and how first-principles thinking exposes opportunities that remain hidden when an industry accepts precedent as fact. It also explains why strong teams delete complexity before they automate it, why positive-sum founders enlarge markets instead of fighting over a fixed share, and why talent density matters more than headcount. The final principle brings everything together. A prototype may attract attention and capital, but the company only creates lasting value when it can produce, learn, improve, and scale faster than its competitors. This distinction matters in life sciences and deep tech, where strong science can still fail during translation. A molecule may work while manufacturing, clinical execution, reimbursement, financing, or commercialization remain underdeveloped. The same problem appears in industrial technology, energy, AI, and robotics, where an impressive demonstration can conceal a production system that will never support scale. Three statements from the book frame the discussion: “How many people you helped, and how much. That’s the total utility.”“The most common mistake of smart engineers is to optimize a thing that should not exist.”“What really matters is the machine that builds the machines, the factory.”Taken together, the seven principles form a founder test. For investors, they provide a structured way to assess mission, judgment, cost discipline, team quality, and the ability to scale. For company builders, they offer practical questions that belong in financing discussions, board meetings, and leadership offsites. Are you building something useful enough to change customer behavior? Does the team reason from fundamental constraints, or does it repeat the industry’s assumptions? Are you simplifying the company, or automating bureaucracy? Can the organization turn promising technology into a repeatable system that produces real customer value? Whatever your opinion of Elon Musk, dismissing the method because you dislike the man can become an expensive mistake. The personality remains optional, while the principles deserve serious examination. Choose one of the seven and bring it into your next board meeting. Chapters (00:00) Introduction: Why the market keeps underestimating Elon Musk (03:31) The Big Idea (08:13) Eric Jorgenson and why he is the right author (10:47) Lesson 1: Build for Utility, Not Glory (16:39) Lesson 2: Missionary Courage Beats Market Permission (21:28) Lesson 3: First Principles Reveal Hidden Upside (25:59) Lesson 4: The Algorithm: Delete Before You Optimize (31:09) Lesson 5: Grow the Pie: Reject Zero-Sum Thinking (35:57) Lesson 6: Talent Density Is the Company (40:54) Lesson 7: Production and Speed Are the Real Moat (45:46) The Seven Practical Takeaways (51:55) Personal Reflection, Critique, and Closing Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Private companies are staying private longer, and that changes who gets liquidity, when, and why. Founders, employees, and early investors can wait a decade or more for an IPO or acquisition. Meanwhile, venture funds face growing pressure to return capital, and many of Europe's best companies struggle to access the growth capital needed to scale. In this conversation, Christian Soschner speaks with Alberto Chalon, Co-Founder of Giano Capital, about the rise of single-asset secondary investments and why they have become an important part of the European innovation ecosystem. Topics include: • What secondary transactions are and why they matter • Why many companies now stay private far longer than before • How founders, employees, and early investors can access liquidity before an exit • The differences between venture capital, private equity, and late-stage secondary investing • Europe's challenge with risk capital, fragmentation, and scaling companies • Lessons from investments such as Revolut, GetYourGuide, and Deliveroo • The role of resilience, sport, and long-term thinking in business and investing Alberto also shares his personal journey from entrepreneurship and building businesses with his brother to launching Giano Capital and creating a new asset class focused on late-stage technology investments. 5 OUTSTANDING QUOTES / LESSONS 1. "Failure in America is part of the learning process. In Europe, failure is a disaster." Lesson: Europe's challenge may be cultural as much as financial. 2. "The due diligence is the beginning of the journey, not the end." Lesson: Great investors keep working after the deal closes. 3. "Everything has to be already tested before we invest." Lesson: Giano seeks to eliminate execution risk before investing. 4. "The loneliness of the entrepreneur is real. I lived that." Lesson: The best investors bring empathy, not only capital. 5. "You need to reach the top, and then you have the descent." Lesson: Investing and endurance sports both reward patience and resilience. TIMESTAMPS (00:00:00) Intro (00:03:00) Why secondaries suddenly matter (00:07:19) Why IPOs are no longer enough (00:12:44) Where Giano fits between VC and PE (00:17:06) Why private information changes returns (00:21:41) How Giano helps founders beyond capital (00:26:19) Not pre IPO but three years earlier (00:31:23) Europe must think beyond countries (00:37:56) Alberto Chalon on loss and entrepreneurship (00:42:12) From search engines to professional investing (00:46:21) How fashion arbitrage shaped his investing (00:53:47) Building a privacy search engine in Europe (01:00:51) Ruthless focus without forcing others (01:07:38) What late-stage governance requires (01:11:50) Why Giano chose late-stage secondaries (01:15:32) Inside Giano Capital's deal funnel (01:19:07) Why community matters in secondaries (01:24:29) GetYourGuide and Revolut as examples (01:27:29) How long a secondary deal takes (01:29:11) Cycling as leadership training (01:36:23) Giano Capital's ten-year ambition Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Only one in three eligible lung cancer patients receives the targeted therapy they should get. That is not a failure of science. It is a failure of delivery. After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data. Yet too many breakthroughs still fail to reach the bedside. Patients fall through fragmented systems. Data does not move cleanly. Community oncologists are overloaded. Tests are missed, delayed, or misread. Promising assets die in quarterly portfolio reviews. And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale. In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm’s Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone. It will be decided by translation. From lab bench to boardroom. From data to decisions. From treatment to prevention. Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation. This conversation moves from the precision medicine delivery crisis to China’s biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs: The ability to translate complex science into business strategy, capital allocation, and patient impact. What You’ll Learn in 22 Minutes Why only one third of eligible lung cancer patients receive targeted therapy (00:01:53) And why precision medicine still breaks in everyday clinical practice. Why science keeps compounding even when systems fail (00:04:33) Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates. Why innovation does not move in a straight line (00:05:20) How technologies can look dead for years before suddenly changing the market. Why China’s biotech speed matters (00:07:36) How AI, organoids, scale, and execution are changing the global innovation map. Why great science dies inside Big Pharma (00:09:20) And how deprioritized assets can become billion-dollar companies when externalized properly. Why the industry must move from sickness to lifelong wellness (00:10:03) Alasdair’s vision for a more proactive, preventive, data-driven healthcare system. Why pharma needs better ways to rescue shelved assets (00:13:06) Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value. How a 400-person Scottish island shaped Alasdair’s worldview (00:15:07) The personal story behind his resilience, discipline, and leadership style. Why careers and companies are never linear (00:17:19) What Alasdair learned after moving to Boston and losing his role within weeks. Why the future belongs to translators (00:20:06) The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards. How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team (00:21:47) Quotes to Carry With You 📌 “We’ve been doing precision medicine in lung cancer for decades, over two decades, and we’re still not getting it right.”  (00:01:53) 📌 “This is where this incredible world of genomic science bumps up against the realities of everyday clinical practice.”  (00:03:31) 📌 “When I was doing my PhD 28 years ago, the idea that you could even have a targeted cell therapy was almost like science fiction.”  (00:04:41) 📌 “The speed was just astonishing.”  (00:07:47) 📌 “We’ve been a sickness industry. We’ve treated disease, chronic disease. But can we move more towards lifelong wellness and preemptive health?”  (00:10:03) 📌 “There’s not a systematic way to collect all of the incredible science and incredible assets that go on the shelf every quarter.”  (00:13:06) 📌 “There’s great science that never sees the light of day because it’s killed in a quarterly portfolio review.”  (00:15:00) 📌 “Your career is never linear.”  (00:17:19) 📌 “You have to be able to build the bridge between the lab and the business world.”  (00:20:06) Why This Conversation Matters Precision medicine is often described as the future of healthcare. But the future does not arrive because the science is ready. It arrives when diagnostics, data, reimbursement, clinical workflows, manufacturing, capital, leadership, and incentives finally work together. That is the real challenge now facing biopharma. Not whether innovation can happen.  It already is. The question is whether leaders can build the systems that allow innovation to reach patients. Alasdair Milton is one of the rare voices who can explain that challenge across science, strategy, capital, and execution. If you are a founder, investor, operator, scientist, board member, policymaker, or family office looking at the future of biotech, precision medicine, advanced therapies, pharma M&A, AI in healthcare, or China’s rise in biopharma, this episode is worth your time. 👉 Listen now. Share it with someone building the future of medicine. Follow Beginner’s Mind for more conversations with the people shaping biotech, capital, and healthcare. Topics: precision medicine, biopharma, biotech, KPMG, Alasdair Milton, cell and gene therapy, in vivo CAR-T, targeted therapy, lung cancer, oncology, AI in healthcare, organoids, China biotech, pharma M&A, SpringWorks, Cerevel, advanced therapies, diagnostics, translational science, venture capital, healthcare strategy. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Some books explain how the world works. Influence explains why people move. Why someone takes the meeting. Why an investor leans in. Why a customer trusts. Why a team follows. Why a board stays stuck. Why a founder keeps defending a decision that stopped making sense months ago. Robert Cialdini’s Influence: The Psychology of Persuasion is one of those books that becomes more valuable the longer you build, invest, sell, negotiate, hire, and lead. Because at some point, you realize something uncomfortable: Most decisions are not made after perfect analysis. They are made under pressure. With incomplete information. With too many options. Too little time. And a nervous system looking for shortcuts. That is where Cialdini’s work becomes powerful. He shows that human beings rely on recurring decision triggers: reciprocation, liking, social proof, authority, scarcity, commitment and consistency, and unity. These are not tricks. They are part of the operating system of human behavior. And if you build or invest in companies from Series A to IPO and beyond, these forces are everywhere. They show up in fundraising. In sales. In hiring. In pricing. In board meetings. In investor updates. In partnerships. In leadership. And in the quiet signals people read before they ever say yes or no. A founder can have the better product and still lose because nobody trusts the signal. A CEO can have the right strategy and still fail because the team never feels real unity. An investor can see the data and still follow the crowd because social proof feels safer than independent judgment. A service provider can have rare expertise and destroy their own value by being too available. A board can keep supporting a flawed decision because everyone wants to stay consistent with what they already said. That is why this book matters. Not because it teaches manipulation. But because it teaches respect for human nature. The best builders do not work against psychology. They work with it. They understand that a small act of generosity can open a door. That people need to like you before they seriously negotiate with you. That visible proof often matters before deep proof gets examined. That authority begins before you speak. That scarcity protects value. That commitment can create momentum — or trap you. And that the strongest companies often feel less like transactions and more like “we.” In this episode, I translate Cialdini’s seven principles into practical lessons for founders, CEOs, investors, and operators building companies in the real world. Not as abstract psychology. As boardroom practice. As fundraising practice. As sales practice. As leadership practice. As reputation practice. And as a defense system against being influenced by people who understand these principles better than you do. What We Cover Reciprocation Why small, right-sized generosity works better than aggressive asking. Liking Why manners, presence, and positive repeated contact still matter more than most people admit. Social Proof Why people judge you by the company you keep — and why markets often follow visible signals before they examine fundamentals. Authority Why titles, suits, posture, calmness, and credibility shape decisions before logic enters the room. Scarcity Why unlimited availability destroys value — and why thoughtful limits can increase demand. Commitment and Consistency Why small yeses become large decisions, and why founders must learn to ask: “Knowing what I know now, would I still choose this?” Unity Why the deepest form of influence is not persuasion, but the feeling that “we are in this together.” Timestamps (00:00) Introduction (02:05) Big Idea – Instant Influence: Primitive Consent for an Automatic Age (05:35) Author’s Background (07:38) Reciprocation – The Old Give and Take… and Take (13:34) Liking – The Friendly Thief (18:55) Social Proof – Truths Are Us (24:41) Authority (32:10) Scarcity – The Rule of the Few (38:00) Commitment and Consistency – Hobgoblins of the Mind (45:00) Unity – We-Ness and the Power of Shared Identity (51:19) Key Takeaways (53:53) Personal Reflection (56:18) Final Words Why This Episode Matters If you raise capital, this episode helps you understand why investors lean in before they fully understand the deck. If you sell, it helps you see why trust is often built before the formal pitch begins. If you lead, it helps you design cultures where people commit because they identify with the mission, not because they were told to comply. If you invest, it helps you protect yourself against false signals: fake authority, fake scarcity, fake social proof, and beautifully packaged nonsense. And if you build companies, it reminds you of something simple: Human nature is not a side issue. It is the terrain. The best founders, investors, and leaders learn to read it. Because capital does not move only toward logic. People do. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most leaders think negotiation begins when both sides sit down to talk numbers.  By then, trust, incentives, timing, internal alignment, and first impressions have already shaped the outcome.  That is why smart founders, executives, investors, and board members can have the right facts and still walk away with the wrong result. In this episode of Beginner’s Mind, Stefanie Schubert explains why negotiation is not a last-minute performance at the table. It is a leadership capability that starts much earlier, in the way people prepare, build trust, frame value, listen, manage emotions, and understand what the other side truly needs. Stefanie is a Professor of Economics at SRH University Heidelberg, a Negotiation Advisor, Keynote Speaker, and ICF-certified Executive Coach. Her work combines behavioral economics, game theory, negotiation, executive coaching, and real-world business practice, with experience in complex business environments, alliance management, and biopharma.  This conversation moves from the practical to the profound: why intelligent people still make weak decisions, why preparation often matters more than persuasion, why pushing people creates resistance, how ballroom dancing explains negotiation better than many textbooks, and why investors, scientists, founders, and corporate leaders often speak past each other without realizing it. We also explore John Nash, A Beautiful Mind, first offers, anchoring, emotional decision-making, AI-driven profiling, trust in virtual environments, and why rejection in fundraising is not necessarily the end of the negotiation. As Stefanie puts it: (01:50:33) “You bring in something. It’s not that you beg for money with the investor.” That may be the core lesson of the episode. Good negotiation is not domination. It is not theatre. It is not a bag of tricks. It is the discipline of understanding value, shaping the game, and entering the room with enough clarity to build something useful with another person. Selected moments (00:00:00) Why smart people lose negotiations early (00:04:24) Negotiation starts before the table (00:07:57) Why smart people still decide poorly (00:13:25) Influence creates value not manipulation (00:18:21) Human shortcuts quietly kill opportunities (00:25:08) Ballroom dancing reveals negotiation resistance (00:28:44) Active listening creates leadership leverage (00:34:06) Authenticity beats dominance in leadership (00:37:05) How to de-escalate emotional negotiations (00:45:05) Game theory without mathematical intimidation (00:52:57) A Beautiful Mind and collaboration traps (01:00:47) First offers and anchoring pressure (01:06:37) Internal alignment before external negotiation (01:12:25) Why emotions can be rational (01:17:20) Fast thinking versus sustainable judgment (01:32:25) AI profiling can poison first impressions (01:40:59) Trust building before formal deals (01:45:04) Why investor rejection is not final (01:47:24) Designing negotiations from first contact (01:48:11) Create value before dividing value (01:50:28) Confidence before asking for capital Follow Beginner’s Mind for long-form conversations on leadership, capital, technology, negotiation, and the people shaping what comes next. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most people still treat climate solutions as a cost. Wanwipa Siriwatwechakul argues that this is exactly why so many leaders miss the real opportunity. The next industrial era will not be built by patching old systems, but by redesigning them from the ground up. In this episode of Beginner’s Mind, Wanwipa explains why industrial decarbonization is not mainly about sacrifice, compliance, or adding expensive fixes to yesterday’s infrastructure. It is about building better systems, stronger companies, and entirely new categories of value creation. A chemical engineer trained at MIT and Princeton, former professor, and Partner at Vectors Capital, Wanwipa works at the intersection of climate tech, synthetic biology, industrial innovation, and early-stage venture capital. Her perspective is grounded in both science and scale: what matters is not only whether a breakthrough works in the lab, but whether it can survive the journey from one gram to one ton, from prototype to product, from curiosity to adoption. We talk about why the strongest climate companies redesign industries instead of decorating old ones, why synthetic biology is emerging as a new industrial toolkit, how startups like Huue Bio, Ingrediome, and Solidec reveal very different scale-up strategies, and why the best founders treat breakthroughs as hypotheses to test rather than theories to defend. As Wanwipa puts it: (01:57:02) “See climate solutions not as cost, but as funding the next industrial era.”  What you’ll hear in this episode Why decarbonization becomes far more powerful when industries are redesigned, not merely optimized How synthetic biology can replace toxic, waste-heavy industrial chemistry with cleaner production models Why great science is only the starting point, and why scale is where most companies really live or die What founders can learn about resilience, coachability, timing, and relentless customer discovery How climate tech can create competitive advantage, new revenue streams, and distributed industrial resilience Why Southeast Asia may become a powerful region for the next wave of climate and bioindustrial growth Selected moments (00:00:56) From Professor to Climate Tech Venture Capital (00:09:27) Why Climate Change Became Personal in Thailand (00:14:11) From Pure Discovery to Real Market Impact (00:23:00) Decarbonization by Redesigning Industry (00:30:06) The Climate Tech Mistake Costing Investors Money (00:34:17) Solidec and the Future of Distributed Manufacturing (00:38:50) Why Big Companies Resist Industrial Reinvention (00:46:21) How Great Founders Turn Pivots Into New Markets (00:50:50) Customer Discovery in Deep Tech and Climate Startups (00:53:08) Great Science Must Become Products People Use (01:00:39) Synthetic Biology as the New Industrial Toolkit (01:10:15) How Climate Startups Find Early Adopters (01:13:19) Founder Resilience and the Stomach of Steel (01:21:15) Venture Capital and the Crucial Why Now (01:57:02) Climate Solutions as Funding the Next Industrial Era  Follow the show for more long-form conversations on technology, capital, leadership, and the people shaping what comes next. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Power demand is rising faster than the systems meant to support it. AI, electrification, and industry all need stable energy, but the dominant story sold to the public was far simpler than reality.  In this episode, Bret Kugelmass explains why the real bottleneck was never just climate ambition, but how the West misunderstood energy itself. For years, nuclear was framed as too dangerous, too slow, too expensive, and politically untouchable. Meanwhile, electricity demand kept rising, industrial resilience became strategic again, and the gap between energy ambition and physical reality widened. This conversation gets underneath the narrative. (Recorded November 2023) Bret Kugelmass, Founder and CEO of Last Energy, argues that the nuclear debate was never only about science or safety. It was also about incentives, regulation, public perception, delivery models, and the failure to distinguish what is inherent to the technology from what is imposed by the system around it. Drawing on his path from Silicon Valley entrepreneurship into deep energy infrastructure, Bret explains why he believes the West solved for the wrong variables, why wind and solar alone cannot carry modern industrial societies in many regions, and why the real breakthrough in nuclear may not come from reinventing the reactor, but from reinventing how power plants are built, sold, and deployed. As he puts it:  (00:33:11) “Solve the wrong problem brilliantly and you’ll be the only one who cares.” This episode is not just about nuclear energy.  It is about first-principles thinking, product-market fit in deep tech, and the kind of contrarian founder logic required to build where politics, infrastructure, and capital collide. What You’ll Learn in This Episode 1️⃣ Why Bret says the West misunderstood the real energy bottleneck 2️⃣ Why net zero may be the wrong framing for climate ambition 3️⃣ What most people still get wrong about nuclear waste, safety, and Fukushima 4️⃣ Why nuclear’s real challenge is cost and construction, not physics 5️⃣ How Last Energy reframed the business by selling electricity, not reactors 6️⃣ What founders can learn from solving the right problem before scaling Selected Timestamps (00:04:29) Introduction (00:04:29) Defining climate goals beyond net zero (00:13:46) Bret discovers nuclear mission and truth (00:19:44) Chernobyl versus Fukushima what truly matters (00:21:39) Nuclear's unmatched physics for abundant energy (00:30:08) Ideal world nuclear plants in 18 months (00:36:02) Solving the right problem before building (00:42:58) First principles simplicity as Last Energy’s edge (00:51:16) Securing 30 billion through true product market fit (00:54:05) Last Energy vision for tens of thousands of gigawatts (00:56:12) Taking ultimate responsibility to drive massive global progress 🎙️ Beginner’s Mind Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping biotech, deep tech, energy, and industrial transformation. Follow the show for more long-form conversations on technology, capital, and the people building what the future will actually run on. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link

Most investors think they’re rational. Most founders think they’re disciplined. Most boards think they’re strategic. They’re usually wrong. In this episode, we unpack Fast Forward Thinking by Luis Pareras — a physician turned deep-tech venture capitalist who distilled decades of investing under scientific uncertainty into 40 brutally structured rules. This is not a summary. It’s a decision upgrade for founders, operators, board members, and capital allocators navigating the high-stakes terrain from Series A to IPO and beyond — where bias compounds, capital misallocates, and timing determines survival. Across seven tightly structured lessons, we explore how elite investors actually think: Why consensus is often a red flag Why opportunity abundance demands ruthless selectivity Why the first meeting should never close Why innovation compounds through milestones — not miracles Why exit logic must exist from day one Why managing error asymmetry beats being “right” And why teams — not ideas — determine survival under pressure This episode translates Pareras’ venture logic into executive practice — with direct applications for capital allocation, hiring, governance, and strategic design. You’ll walk away with frameworks, sharper filters, and board-level questions that immediately improve judgment. Key Takeaways Bias Is the Silent Capital Killer Consensus feels safe. It often destroys upside. Selectivity Is Survival Abundance demands disciplined rejection. Curiosity Beats Closure The first meeting earns the second. Innovation Is Staged Breakthroughs are milestone-based progressions. Exit Thinking Is Structural Capital is deployed against time horizons. Error Asymmetry Shapes Returns Managing Type I and Type II errors defines long-term performance. Teams Outperform Ideas Execution discipline and cognitive flexibility win under uncertainty. Timestamps (00:00) Introduction (04:17) The Big Idea (08:33) Who Is Luis Pareras (12:03) Takeaway 1: Cognitive Bias Is the Hidden Enemy of Good Decisions (18:55) Takeaway 2: Deal Flow Is Abundant — Selectivity Is the Real Skill (24:16) Takeaway 3: The First Meeting Is Not About Closing (29:04) Takeaway 4: Innovation Is a Process (35:20) Takeaway 5: Exit Awareness Shapes Investment Logic (39:59) Takeaway 6: Error Types Matter More Than Individual Outcomes (44:38) Takeaway 7: Teams and Judgment Matter More Than Ideas (49:15) Key Takeaways: The Fast Forward Operating System (54:25) Personal Reflection and End Why Listen Upgrade how you evaluate opportunities — before committing capital. Sharpen how you structure innovation — before chasing breakthroughs. Design decision systems that reduce catastrophic error. And build organizations that survive uncertainty. If this episode sharpens your thinking: Follow the show. Share it with someone who allocates capital. And bring these questions into your next board meeting. Because in venture, public markets, and corporate strategy alike — returns are rarely accidental. Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now. Support the show Join the Podcast Newsletter: Link